BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx second quarter 2025 financial results conference call. All participants are present in listen-only mode. Song management formal presentation instructions will be given for the question and answer session. I would now like to turn over the call to Irina Kossler, Investor Relations. Irina, please go ahead. Thank you, Operator, and welcome, everyone. Thank you for joining us on our quarterly results conference call. Earlier today, we issued a press release, a copy of which is available in the investor relations section of our website. It was also filed as a 6K. I'd like to remind you that certain statements we make during the call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20-X and our quarterly reports on Form 6-K that are filed with the U.S. Securities and Exchange Commissions. At this time, it is now my pleasure to turn the call over to Mr. Phil Sterling, Chief Executive Officer of BioLineRx. Thank you, Irina, and good morning, everyone. And thank you for joining us on today's call. As has been our practice, I will begin with a few prepared remarks before turning the call over to Molly Zeppe, our Chief Financial Officer, to briefly recap our financials. Afterwards, we will take your questions. Ellis Narani, our Chief Development Officer, is also available for Q&A. I'd like to begin this morning with an update on our search for additional early-stage assets, both clinical and preclinical, in the areas of oncology and rare diseases to support ...